ArticleFrontiers in endocrinology2026
Analysis of senescence in pituitary tumors from different lineages and the potential role of senolytic drugs as targeted therapies.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pituitary tumors (PT) constitute the second most frequent intracranial tumor. A subset of PT can behave aggressively despite multimodal treatment. Hallmarks such as cellular senescence, epithelial-mesenchymal transition (EMT), and stemness have been implicated in tumor progression, but their role in PT pathogenesis remains is unclear. Methods: We performed spatial transcriptomics (ST) in dopamine agonist resistant prolactin secreting PT, as well as single nucleus RNAseq (snRNAseq) in growth hormone secreting and non-functioning of gonadotropic differentiation PT to describe the senescence, proliferative and stemness landscapes. Bioinformatic analyses included clustering, senescence scoring (SenePy), cell cycle inference (ccAFv2), differentiation potential (CytoTRACE2), and EMT signature evaluation. Primary tumor cell cultures were established to validate senescence (β-galactosidase activity) and to assess the senolytic effect of dasatinib. Result: All PT included in the study were transcriptomically heterogeneous, showing between three and ten transcriptional clusters. Senescence analysis reveals two main clusters regardless of PT lineage: One with a high and the other one with low senescence score. Most spots contain terminally differentiated cells at phase G1/G0 of the cell cycle. Distinct alteration in different signaling pathways were found in clusters with low senescence score: PI3K-cascade-FGFR1 and inositol phosphate metabolism among prolactin secreting tumors, phosphatidyl inositol signaling system and serine/threonine kinase activity the in GH-secreting PT, sphingolipid signaling pathway and serine/threonine kinase alterations among non-functioning of gonadotropic differentiation PT. Dasatinib treatment of primary cell cultures of pituitary tumors of different lineages showed significant dose-dependent cell death, accompanied by caspase-3/7 activation and morphological changes consistent with apoptosis. Conclusion: Our data show that PT may contain senescent and terminally differentiated cells without any EMT evidence, and dasatinib could represent an alternative for therapy resistant PT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.